Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Results 1 - 20 of 27 : 1 2 Next »

Recs

0
Member Avatar pchop12316 (77.34) Submitted: 7/27/2015 2:09:32 PM : Underperform Start Price: $24.64 DYAX Score: -2.69

not impressed

Recs

2
Member Avatar zzlangerhans (99.72) Submitted: 6/26/2015 1:50:26 PM : Underperform Start Price: $27.35 DYAX Score: +5.25

Dyax is definitely doing much better than I expected when I rejected a zzporte buy a couple of years ago in the low single digits (ouch) but I think a market cap of close to four billion is a little ridiculous. The company gained another billion and a half in cap in April with encouraging results from a phase Ib trial of a new kallikrein-inhibiting mAb for hereditary angioedema prophylaxis, and they've done an admirable job of sustaining that valuation. However, given that there are already products well-established commercially for that same indication I'm not sure that reality is well-reflected here. It's hard to start calling tops when market caps already seem so unrealistic but I'm willing to flag Dyax for potnetial underperformance when the whole biopharma sector looks about ready to burst at the seams.

Recs

0
Member Avatar SamsaricSufferer (54.51) Submitted: 9/26/2013 8:42:15 PM : Underperform Start Price: $6.70 DYAX Score: -257.57

Technically very over bought.

Recs

1
Member Avatar gringo33339 (< 20) Submitted: 4/26/2013 5:32:29 PM : Outperform Start Price: $2.73 DYAX Score: +804.19

Buying opportunity today for this stock which will benefit greatly if LLY sees success in its Ramu pipeline drug candidate.

Recs

1
Member Avatar DEWBMW (< 20) Submitted: 5/24/2012 12:59:28 AM : Outperform Start Price: $1.69 DYAX Score: +1,354.27

Should break even on cash flow in 2013. Great time to get in. Only company I know that makes a drug for HAE.

Recs

1
Member Avatar stainsolution (81.55) Submitted: 4/9/2012 7:42:31 PM : Outperform Start Price: $1.57 DYAX Score: +1,475.90

Bio play

Recs

1
Member Avatar RBuskey106 (67.69) Submitted: 3/21/2012 11:29:57 AM : Outperform Start Price: $1.58 DYAX Score: +1,467.87

Chart looking good

Recs

0
Member Avatar rocknpopstocks (< 20) Submitted: 3/11/2011 12:51:19 PM : Outperform Start Price: $1.57 DYAX Score: +1,467.45

Should get some play.

Recs

0
Member Avatar wofaintagain (< 20) Submitted: 10/15/2009 12:34:34 PM : Underperform Start Price: $3.22 DYAX Score: -601.96

until drug approval

Recs

0
Member Avatar biomedeng (70.45) Submitted: 12/31/2007 8:06:33 PM : Outperform Start Price: $3.87 DYAX Score: +512.47

The thing to know about Dyax is that the HAE indication for DX-88 is mostly beneficial to get the drug approved for human use. Once DX-88 is approved, it is available for off label indications like CABG, currently in phase II trials. If a couple surgeons see better outcomes with DX-88 in their solutions (and the trials are quite promising), the drug will become very popular very quickly regardless of what the on-label indications are.

Recs

0
Member Avatar doggetla (61.14) Submitted: 10/26/2007 6:57:24 PM : Outperform Start Price: $4.50 DYAX Score: +425.54

great bio-tech partners - with lots of "magic beans" in pipeline

Recs

0
Member Avatar Dwaterman86 (< 20) Submitted: 10/4/2007 3:39:25 PM : Underperform Start Price: $3.82 DYAX Score: -526.77

better off investing in magic beans

Recs

0
Member Avatar hendrikvanlaar (< 20) Submitted: 9/11/2007 4:25:01 AM : Outperform Start Price: $3.98 DYAX Score: +491.53

finding a partner to sell their top drug will boost the stock (the successful completion of phase III sent the stock up by 50% in a day, but that didn't last. Make use of it)

Recs

0
Member Avatar fatcanibal (< 20) Submitted: 6/14/2007 4:17:27 PM : Outperform Start Price: $4.55 DYAX Score: +417.89

Well organized and focused

Recs

0
Member Avatar misterp946 (50.91) Submitted: 5/22/2007 3:41:43 PM : Outperform Start Price: $4.34 DYAX Score: +444.15

Hot New Products....stock took a beating....when Genzyme deal feel through...This stock due for a nice come back....sell on announcement

Recs

0
Member Avatar jgonzz (< 20) Submitted: 5/18/2007 3:11:38 PM : Outperform Start Price: $4.45 DYAX Score: +428.99

Too many promising projects inside their pipeline.

Recs

0
Member Avatar carmangar (< 20) Submitted: 4/26/2007 9:38:55 PM : Outperform Start Price: $4.48 DYAX Score: +422.13

Development of new medicine, pending outcome of further research and medical experimentation.

Recs

1
Member Avatar majakblue (< 20) Submitted: 4/14/2007 3:19:13 PM : Underperform Start Price: $6.19 DYAX Score: -261.26

Yeah, yeah, yeah, lets see if any of their candidates get past large scale phase III trials. Lets see if the patients have kidneys and liver left afterwards.

Recs

0
Member Avatar j3bajric (< 20) Submitted: 4/13/2007 2:16:00 PM : Outperform Start Price: $5.92 DYAX Score: +279.25

If it gets approved money will flow.

Recs

0
Member Avatar wbahl (93.86) Submitted: 4/13/2007 11:05:35 AM : Outperform Start Price: $6.21 DYAX Score: +258.99

This company researches cancer and is very successful.

Results 1 - 20 of 27 : 1 2 Next »

Featured Broker Partners


Advertisement